Top

Neurological Sciences

Published in:

14-08-2023 | Subarachnoid Hemorrhage | Original Article

Impact of human serum albumin level on symptomatic cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage

Authors: Ling Chen, Yang Jin, Ling Wang, Kai Wei, Xin Li, Tao Jiang, Xiangyang Cao, Liujun Xue, Qiantao Cheng

Published in: Neurological Sciences | Issue 1/2024

Abstract

Objective

To investigate the impact of human serum albumin (HSA) levels on symptomatic cerebral vasospasm (SCVS) in patients with aneurysmal subarachnoid hemorrhage (aSAH).

Methods

We retrospectively reviewed the medical records. SCVS was defined as the development of a new neurological deterioration when the cause was considered to be ischemia attributable to vasospasm after other possible causes of worsening had been excluded. The aSAH patients were divided into two groups: those with SCVS (group 1) and those without SCVS (group 2). The HSA level data on the 1st, 2nd, and 3rd day after admission was collected. Multivariate logistical regression and receiver operating characteristic (ROC) analysis were performed to evaluate the ability of HSA level to predict the development of SCVS.

Results

A total of 270 patients were included in our study, of which 74 (27.4%) developed SCVS. The average and lowest HSA levels were lower in group 1 (P < 0.001). In univariate logistic regression, white blood cell count, neutrophil count, and average and lowest HSA levels were associated with SCVS. After adjustment for age, CT Fisher grade, Hunt-Hess grade, and WFNS grade, both the average and lowest HSA levels remained independent predictors of SCVS (P < 0.001). The CT Fisher grade was confirmed to be an independent predictor of SCVS across each model. ROC analysis revealed that the lowest HSA level was a better predictor for SCVS than average HSA level and CT Fisher grade.

Conclusion

Clinicians are encouraged to measure HSA levels for the first 3 days after admission to predict the occurrence of SCVS after aSAH.

Wang W, Jiang B, Sun H, Ru X, Sun D, Wang L, Wang L, Jiang Y, Li Y, Wang Y, Chen Z, Wu S, Zhang Y, Wang D, Wang Y, Feigin V (2017) Prevalence, incidence, and mortality of stroke in China: results from a nationwide population-based survey of 480 687 adults. Circulation 135:759–771. https://doi.org/10.1161/circulationaha.116.025250CrossRefPubMed

Connolly E, Rabinstein A, Carhuapoma J, Derdeyn C, Dion J, Higashida R, Hoh B, Kirkness C, Naidech A, Ogilvy C, Patel A, Thompson B, Vespa P (2012) Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 43:1711–1737. https://doi.org/10.1161/STR.0b013e3182587839CrossRefPubMed

Fu Q, Wang Y, Lin S, Yang Y (2021) Evaluation of efficacy and safety of endovascular coiling for patients with aneurysmal subarachnoid hemorrhage: a protocol for systematic review and meta-analysis. Medicine 100:e25728. https://doi.org/10.1097/md.0000000000025728CrossRefPubMedPubMedCentral

Matano F, Fujiki Y, Mizunari T, Koketsu K, Tamaki T, Murai Y, Yokota H, Morita A (2019) Serum glucose and potassium ratio as risk factors for cerebral vasospasm after aneurysmal subarachnoid hemorrhage. J Stroke Cerebrovasc Dis 28:1951–1957. https://doi.org/10.1016/j.jstrokecerebrovasdis.2019.03.041CrossRefPubMed

Frontera J, Fernandez A, Schmidt J, Claassen J, Wartenberg K, Badjatia N, Connolly E, Mayer S (2009) Defining vasospasm after subarachnoid hemorrhage: what is the most clinically relevant definition? Stroke 40:1963–1968. https://doi.org/10.1161/strokeaha.108.544700CrossRefPubMed

Sokolowski J, Chen C, Ding D, Buell T, Raper D, Ironside N, Taylor D, Starke R, Liu K (2018) Endovascular treatment for cerebral vasospasm following aneurysmal subarachnoid hemorrhage: predictors of outcome and retreatment. J Neurointerv Surg 10:367–374. https://doi.org/10.1136/neurintsurg-2017-013363CrossRefPubMed

Vergouwen M, de Haan R, Vermeulen M, Roos Y (2010) Effect of statin treatment on vasospasm, delayed cerebral ischemia, and functional outcome in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis update. Stroke 41:e47–e52. https://doi.org/10.1161/strokeaha.109.556332CrossRefPubMed

Haley EC Jr, Kassell NF, Torner JC (1992) The international cooperative study on the timing of aneurysm surgery. The North American experience. Stroke 23:205–214. https://doi.org/10.1161/01.str.23.2.205CrossRefPubMed

Harrod C, Bendok B, Batjer H (2005) Prediction of cerebral vasospasm in patients presenting with aneurysmal subarachnoid hemorrhage: a review. Neurosurgery 56:633–654 discussion 633-654. https://doi.org/10.1227/01.neu.0000156644.45384.92CrossRefPubMed

10.

Lang J, Figueroa M, Chumley P, Aslan M, Hurt J, Tarpey M, Alvarez B, Radi R, Freeman B (2004) Albumin and hydroxyethyl starch modulate oxidative inflammatory injury to vascular endothelium. Anesthesiology 100:51–58. https://doi.org/10.1097/00000542-200401000-00012CrossRefPubMed

11.

Wang L, Li M, Xie Y, Xu L, Ye R, Liu X (2017) Preclinical efficacy of human albumin in subarachnoid hemorrhage. Neuroscience 344:255–264. https://doi.org/10.1016/j.neuroscience.2016.12.033CrossRefPubMed

12.

Suarez J, Martin R, Calvillo E, Dillon C, Bershad E, Macdonald R, Wong J, Harbaugh R (2012) The Albumin in Subarachnoid Hemorrhage (ALISAH) multicenter pilot clinical trial: safety and neurologic outcomes. Stroke 43:683–690. https://doi.org/10.1161/strokeaha.111.633958CrossRefPubMedPubMedCentral

13.

Rumalla K, Lin M, Ding L, Gaddis M, Giannotta S, Attenello F, Mack W (2021) Risk factors for cerebral vasospasm in aneurysmal subarachnoid hemorrhage: a population-based study of 8346 patients. World Neurosurg 145:e233–e241. https://doi.org/10.1016/j.wneu.2020.10.008CrossRefPubMed

14.

Zhang J (2015) Guidelines for diagnosis and management of aneurysmal subarachnoid hemorrhage: top issues and prospective. Zhejiang Da Xue Xue Bao Yi Xue Ban 44:357–360. https://doi.org/10.3785/j.issn.1008-9292.2015.07.01CrossRefPubMedPubMedCentral

15.

Vergouwen M, Vermeulen M, van Gijn J, Rinkel G, Wijdicks E, Muizelaar J, Mendelow A, Juvela S, Yonas H, Terbrugge K, Macdonald R, Diringer M, Broderick J, Dreier J, Roos Y (2010) Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies: proposal of a multidisciplinary research group. Stroke 41:2391–2395. https://doi.org/10.1161/strokeaha.110.589275CrossRefPubMed

16.

Ciurea A, Palade C, Voinescu D, Nica D (2013) Subarachnoid hemorrhage and cerebral vasospasm — literature review. J Med Life 6:120–125PubMedPubMedCentral

17.

Song Y, Qian S, Li Y, Liu J, Li Z, Jia X, Gao H, Zeng J (2019) Effectiveness and safety of nimodipine in preventing cerebral vasospasm after subarachnoid hemorrhage in children. Zhonghua Er Ke Za Zhi 57:338–343. https://doi.org/10.3760/cma.j.issn.0578-1310.2019.05.005CrossRefPubMed

18.

Kapapa T, König R, Mayer B, Braun M, Schmitz B, Müller S, Schick J, Wirtz C, Pala A (2021) Adverse events and complications in continuous intra-arterial nimodipine infusion therapy after aneurysmal subarachnoid hemorrhage. Front Neurol 12:812898. https://doi.org/10.3389/fneur.2021.812898CrossRefPubMed

19.

Provencio J, Vora N (2005) Subarachnoid hemorrhage and inflammation: bench to bedside and back. Semin Neurol 25:435–444. https://doi.org/10.1055/s-2005-923537CrossRefPubMed

20.

Ikeda K, Ikeda T, Suzuki H, Taniuchi H, Nagura M, Ooshima K (2003) Colloid osmotic pressure (COP) can be a good indicator of occurrence of vasospasm following subarachnoid hemorrhage (SAH). Med Sci Monit 9:CR43–CR47PubMed

21.

Buce-Satoba I, Rozkalne D, Mamaja B, Krumina G, Ozolina A (2022) Leukocytosis and C-reactive protein may predict development of secondary cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage. Medicina (Kaunas) 58:323. https://doi.org/10.3390/medicina58020323CrossRefPubMed

22.

Tsai T, Lin S, Wu C, Tsai Y, Yang S, Lin C (2020) Mechanisms and therapeutic implications of RTA 408, an activator of Nrf2, in subarachnoid hemorrhage-induced delayed cerebral vasospasm and secondary brain injury. PLoS One 15:e0240122. https://doi.org/10.1371/journal.pone.0240122CrossRefPubMedPubMedCentral

23.

Wu C, Tsai H, Su Y, Tsai C, Lu Y, Lin C (2022) 2-PMAP ameliorates cerebral vasospasm and brain injury after subarachnoid hemorrhage by regulating neuro-inflammation in rats. Cells 11:242. https://doi.org/10.3390/cells11020242CrossRefPubMedPubMedCentral

24.

Kolias A, Sen J, Belli A (2009) Pathogenesis of cerebral vasospasm following aneurysmal subarachnoid hemorrhage: putative mechanisms and novel approaches. J Neurosci Res 87:1–11. https://doi.org/10.1002/jnr.21823CrossRefPubMed

25.

Croci D, Sivanrupan S, Wanderer S, Agnoletto G, Chiappini A, Grüter B, Andereggen L, Mariani L, Taussky P, Marbacher S (2022) Preclinical and clinical role of interleukin-6 in the development of delayed cerebral vasospasm and neuronal cell death after subarachnoid hemorrhage: towards a potential target therapy? Neurosurg Rev 45:395–403. https://doi.org/10.1007/s10143-021-01628-9CrossRefPubMed

26.

Ghali M, Srinivasan V, Johnson J, Kan P, Britz G (2018) Therapeutically targeting platelet-derived growth factor-mediated signaling underlying the pathogenesis of subarachnoid hemorrhage-related vasospasm. J Stroke Cerebrovasc Dis 27:2289–2295. https://doi.org/10.1016/j.jstrokecerebrovasdis.2018.02.017CrossRefPubMed

27.

Demling R (1986) Effect of plasma and interstitial protein content on tissue edema formation. Curr Stud Hematol Blood Transfus:36–52. https://doi.org/10.1159/000413163

28.

Keaney J, Simon D, Stamler J, Jaraki O, Scharfstein J, Vita J, Loscalzo J (1993) NO forms an adduct with serum albumin that has endothelium-derived relaxing factor-like properties. J Clin Invest 91:1582–1589. https://doi.org/10.1172/jci116364CrossRefPubMedPubMedCentral

29.

Chen J, Cheng K, Tsai Y, Hong Y, Howng S, Kwan A, Chen I, Wu B (2012) Potassium-channel openers KMUP-1 and pinacidil prevent subarachnoid hemorrhage-induced vasospasm by restoring the BKCa-channel activity. Shock 38:203–212. https://doi.org/10.1097/SHK.0b013e31825b2d82CrossRefPubMed

30.

Sheinenzon A, Shehadeh M, Michelis R, Shaoul E, Ronen O (2021) Serum albumin levels and inflammation. Int J Biol Macromol 184:857–862. https://doi.org/10.1016/j.ijbiomac.2021.06.140CrossRefPubMed

31.

Mangoni A, Zinellu A (2022) A systematic review and meta-analysis of serum concentrations of ischaemia-modified albumin in acute ischaemic stroke, intracerebral haemorrhage, and subarachnoid haemorrhage. Biomolecules 12:653. https://doi.org/10.3390/biom12050653CrossRefPubMedPubMedCentral

32.

van der Zee P, Verberne H, van Straalen J, Sanders G, Van Eck-Smit B, de Winter R, Fischer J (2005) Ischemia-modified albumin measurements in symptom-limited exercise myocardial perfusion scintigraphy reflect serum albumin concentrations but not myocardial ischemia. Clin Chem 51:1744–1746. https://doi.org/10.1373/clinchem.2005.054635CrossRefPubMed

33.

Shevtsova A, Gordiienko I, Tkachenko V, Ushakova G (2021) Ischemia-modified albumin: origins and clinical implications. Dis Markers 2021:9945424. https://doi.org/10.1155/2021/9945424CrossRefPubMedPubMedCentral

34.

Nicholson J, Wolmarans M, Park G (2000) The role of albumin in critical illness. Br J Anaesth 85:599–610. https://doi.org/10.1093/bja/85.4.599CrossRefPubMed

35.

Jin G, Li L, Cui S, Duan J, Wang H (2014) Persistent hypoalbuminemia is a predictor of outcome in cervical spinal cord injury. Spine J 14:1902–1908. https://doi.org/10.1016/j.spinee.2013.10.049CrossRefPubMed

36.

Seebacher V, Grimm C, Reinthaller A, Heinze G, Tempfer C, Hefler L, Polterauer S (2013) The value of serum albumin as a novel independent marker for prognosis in patients with endometrial cancer. Eur J Obstet Gynecol Reprod Biol 171:101–106. https://doi.org/10.1016/j.ejogrb.2013.07.044CrossRefPubMed

37.

Zimmermann J, Weller J, Grub S, Kebir S, Lehmann F, Vatter H, Schuss P, Güresir E, Müller M (2022) Arginase-1 released into CSF after aneurysmal subarachnoid hemorrhage decreases arginine/ornithine ratio: a novel prognostic biomarker. Transl Stroke Res 13:382–390. https://doi.org/10.1007/s12975-021-00944-yCrossRefPubMed

Title: Impact of human serum albumin level on symptomatic cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage
Authors: Ling Chen
Yang Jin
Ling Wang
Kai Wei
Xin Li
Tao Jiang
Xiangyang Cao
Liujun Xue
Qiantao Cheng
Publication date: 14-08-2023
Publisher: Springer International Publishing
Keywords: Subarachnoid Hemorrhage
Subarachnoid Hemorrhage
Aneurysm
Aneurysm
Published in: Neurological Sciences / Issue 1/2024
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-023-07014-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Impact of human serum albumin level on symptomatic cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage

Abstract

Objective

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2024

Back to the future: encephalitis lethargica as an autoimmune disorder?

Extensive intraventricular glioblastoma mimicking intracranial lymphoma

Can the use of telemedicine facilitate online prescribing for multiple sclerosis treatment?

Jean-Martin Charcot (1825–1893) and the first classification of multiple sclerosis in the medical literature

Epworth sleepiness scale is associated with increased striatal dopamine uptake in Parkinson’s disease: a cross-sectional study

Glucocorticoid-dependent multiple sclerosis overlapping anti-NMDA receptor encephalitis: a case report and literature review update